07.12.2010 • News

Ian C. Read to Replace Jeffrey Kindler at Pfizer

Ian C. Read has been elected Pfizer's president, CEO and director, succeeding Jeffrey Kindler, who is leaving the company.

Since 2006, Read has led Pfizer's worldwide biopharmaceutical businesses, which now comprises five global business units - Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets - and accounts for approximately 85% of the company's annual revenues.

Kindler took over at the helm of Pfizer in 2006 and guided the company through its acquisition of Wyeth. He said, "Now that we are about to complete a full year of operating Pfizer and Wyeth together, with our world-class team fully in place, I have concluded the time is right to turn the leadership of the company over to Ian Read ... I am excited at the opportunity to recharge my batteries, spend some rare time with my family, and prepare for the next challenge in my career."

Pfizer said its board will elect a non-executive chairman from its current membership at its next regularly scheduled meeting that will take place within the next two weeks

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.